Dr. Jerald P. Radich on Treatment Considerations with Generic Imatinib in CML

Jerald P. Radich, MD
Published: Saturday, Oct 08, 2016


Jerald P. Radich, MD, clinical research division, Fred Hutchinson Cancer Research Center, discusses which patients should receive the newly approval generic imatinib versus second-generation tyrosine-kinase inhibitors (TKIs) in chronic myeloid leukemia (CML).  
 
It is important that oncologists are proactive in determining which patients should receive generic imatinib and not be registered by insurance companies, says Radich.
 
The NCCN guidelines are somewhat generic, and so oncologists need to look at each patient individually and, based on treatment goals, determined if they should receive generic imatinib or second-generation TKIs. Age may be a factor to consider, says Radich.
 
SELECTED
LANGUAGE

Jerald P. Radich, MD, clinical research division, Fred Hutchinson Cancer Research Center, discusses which patients should receive the newly approval generic imatinib versus second-generation tyrosine-kinase inhibitors (TKIs) in chronic myeloid leukemia (CML).  
 
It is important that oncologists are proactive in determining which patients should receive generic imatinib and not be registered by insurance companies, says Radich.
 
The NCCN guidelines are somewhat generic, and so oncologists need to look at each patient individually and, based on treatment goals, determined if they should receive generic imatinib or second-generation TKIs. Age may be a factor to consider, says Radich.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Cancer Summaries and Commentaries™: Update from Atlanta: Advances in the Treatment of Chronic Lymphocytic LeukemiaFeb 28, 20190.5
Community Practice Connections™: 2nd Annual International Congress on Immunotherapies in Cancer™: Focus on Practice-Changing ApplicationFeb 28, 20192.0
Publication Bottom Border
Border Publication
x